Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
German Tech Holding (GTH) is exploring an investment in Zirnostics GmbH, a biotech startup developing a zirconium-89-labelled tracer for prostate cancer diagnostics. The technology offers significantly higher tumour-to-background contrast, potentially improving detection of tumour foci and metastases.
German Tech Holding (GTH) is considering a 10% investment in Zirnostics GmbH, a biotech startup developing a zirconium-89-labeled radiopharmaceutical for improved prostate cancer diagnostics. The technology shows potential for early detection of tumor foci and metastases.
German Tech Holding GmbH & Co. KGaA is examining an investment of 10% in Zirnostics GmbH, a biotech startup developing a zirconium-89-based radiopharmaceutical for prostate cancer diagnostics.